US20050003014A1 - Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs - Google Patents

Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs Download PDF

Info

Publication number
US20050003014A1
US20050003014A1 US10/494,709 US49470904A US2005003014A1 US 20050003014 A1 US20050003014 A1 US 20050003014A1 US 49470904 A US49470904 A US 49470904A US 2005003014 A1 US2005003014 A1 US 2005003014A1
Authority
US
United States
Prior art keywords
nanoparticles
ophthalmic
compositions
otic
inorganic nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/494,709
Inventor
Howard Ketelson
David Meadows
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/494,709 priority Critical patent/US20050003014A1/en
Assigned to ALCON, INC. reassignment ALCON, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MEADOWS, DAVID L., KETELSON, HOWARD ALLEN
Publication of US20050003014A1 publication Critical patent/US20050003014A1/en
Assigned to ALCON, INC. reassignment ALCON, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MEADOWS, DAVID L., KETELSON, HOWARD ALLEN
Assigned to NOVARTIS AG reassignment NOVARTIS AG MERGER (SEE DOCUMENT FOR DETAILS). Assignors: ALCON, INC.
Priority to US13/186,108 priority patent/US8257745B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Definitions

  • the present invention is directed to the field of ophthalmic and otic drug delivery. More specifically, the present invention is directed to the use of synthetic, inorganic nanoparticles as inert carriers for ophthalmic and otic drugs, and to the use of pharmaceutical compositions based on the invention to deliver ophthalmic drugs topically to the eye and ear.
  • the nanoparticles utilized in the present invention are not formed from synthetic or natural polymers such as those described in the above-cited publications. Rather, the present invention is directed to the use of inorganic nanoparticles.
  • the nanoparticles utilized in the present invention include, for example, clay substances that are water swellable. An extensive review of clays and their chemical and physical properties can be found in:
  • the preferred nanoparticles are formed from synthetic smectite clays which are prepared from simple silicates.
  • the following publications may be referred to for further background regarding the use of synthetic clay nanoparticles in pharmaceutical compositions:
  • U.S. Pat. No. 6,177,480 (Tsuzuki, et al.) describes the use of synthetic clay material (i.e., LaponiteTM) as a wetting agent for contact lenses and to assist in the removal of lipid deposits from contact lenses by surfactants.
  • synthetic clay material i.e., LaponiteTM
  • the present invention is based on the use of nanoparticles of inorganic materials to facilitate the formulation of ophthalmic and otic compositions, particularly compositions adapted for topical application to ophthalmic or otic tissues.
  • the nanoparticles function as a chemically inert carrier or depot for ophthalmic and otic drugs and other components of ophthalmic and otic compositions.
  • the present invention is believed to have advantages over the prior art use of organic polymers for ophthalmic drug delivery.
  • the inorganic nanoparticles utilized in the present invention are particularly well suited for use as drug delivery agents in instances wherein controlled delivery of the drug is needed.
  • the particles offer advantages over current state of the art delivery agents as a result of the higher surface area of the particles and the ability of the particles to form clear gels or solutions when dispersed in aqueous media.
  • the nanoparticles can be dispersed while retaining a clear solution. Due to the minute size of the nanoparticles, the compositions of the present invention remain clear and non-blurry, which is very important for ophthalmic compositions. It has also been found that the particles can be utilized as carriers for ophthalmic and otic drugs without compromising the microbiological activity of antimicrobial preservatives contained in the compositions.
  • the inorganic nanoparticles In addition to acting as inert carriers for ophthalmic and otic drugs, the inorganic nanoparticles also provide advantageous rheological properties for the compositions of the present invention.
  • the nanoparticles utilized in the present invention are inorganic materials.
  • the particles have colloidal dimensions, a large surface area and a high ion exchange capacity.
  • the particles are generally referred to hereinafter as “inorganic nanoparticles”.
  • the use of the synthetic inorganic nanoparticles is preferred.
  • the inorganic nanoparticles used in the present invention preferably have particle dimensions less than 100 nanometers (“nm”), but greater than 1 nm.
  • the morphology of the nanoparticles is not limited to being spherical; plate-like, cubic, ellipsoid or other particle shapes are also useful.
  • the particles have surface areas ranging from 30-1000 square meters/gram (“m 2 /g”), and have an overall negative surface charge at a pH in the range of 6.0 to 7.8.
  • the inorganic nanoparticles utilized in the present invention may also be surface modified, depending on the particular type of composition involved and stability requirements. Different types of nanoparticles may be combined to optimize the formulation properties.
  • the inorganic nanoparticles utilized in the present invention are preferably formed from clays that swell in aqueous solutions. These types of clays are referred to herein as being “hydrous”.
  • the use of nanoparticles of synthetic hydrous clays is preferred due to the commercial availability, purity, and well-defined chemical composition and physical properties of these materials.
  • the synthetic clay nanoparticles are easier to formulate and can form colorless and transparent gels more readily than inorganic nanoparticles formed from naturally occurring clays.
  • Synthetic inorganic nanoparticles that are particularly useful include a synthetic smectite clay that is commercially available under the trademark Laponite® (Southern Clay Products, Gonzales, Tex., USA).
  • Laponite® is a layered hydrous magnesium silicate prepared from simple silicates. The following publication may be referred to for further details concerning the physical properties and functions of Laponite®: “Laponite Technical Bulletin “Laponite-synthetic layered silicate—its chemistry, structure and relationship to natural clays” L204/01 g.
  • Another synthetic magnesium aluminum silicate material is also commercially available under the trademark OPTIGEL® SH (Sud-Chemie, Louisville, Ky.).
  • Inorganic nanoparticles formed from naturally occurring hydrous clays may also be utilized, either in combination with a synthetic clay or alone.
  • suitable naturally occurring clays include aliettite, beidellite, bentonite, hectorite, kaolinite, magadite, montmorillonite, nontronite, saponite, sauconite, stevensite and volkonskoite.
  • inorganic nanoparticle materials that may be utilized instead of or in combination with the clay nanoparticles described above include zeolites, silica, aluminum oxide, cerium oxide, titanium oxide and zinc oxide.
  • Nanometer sized silica particles such as those supplied by Nalco (e.g., Nalco® 115 and 1140) and EKA Chemicals (NYACOL® grades), are readily available.
  • Mineral oxide nanoparticles based on other metals are also commercially available.
  • mineral oxides e.g., aluminum oxide, cerium oxide, titanium oxide and zinc oxide having well defined nano-dimensions are available from Nanophase Technologies (Romeoville, Ill., USA) under the trade name “NanoTek®”.
  • the above-described inorganic nanoparticles are capable of functioning as carriers for ophthalmic and otic drug molecules and other components of ophthalmic and otic pharmaceutical compositions.
  • the present invention is applicable to the use of nanoparticles as carriers for various types of pharmaceutically active agents, such as agents for controlling intraocular pressure and treating glaucoma, neuroprotectants, anti-allergy agents, anti-infectives, anti-inflammatory agents, mucosecretagogues, angiostatic steroids, pain relievers, decongestants or astringents, and so on.
  • anti-glaucoma agents such as apraclonidine, brimonidine, betaxolol, timolol, pilocarpine, carbonic anhydrase inhibitors, prostaglandins and serotonergics; dopaminergic antagonists; anti-infectives, such as moxifloxacin, gatifloxacin, levofloxacin, ciprofloxacin and tobramycin; non-steroidal and steroidal anti-inflammatories, such as rimexolone, dexamethasone, prednisolone, fluorometholone, lotoprednol, naproxen, diclofenac, suprofen and ketorolac; proteins; growth factors, such as epidermal growth factor; mucosecretagogues, such as 15-HETE; angiostatic steroids, such as
  • concentration of the inorganic nanoparticles utilized in specific ophthalmic or otic compositions of the present invention will depend on the physical form of the composition (e.g., solution, dispersion, suspension or gel) and other factors apparent to those skilled in the art.
  • concentration of nanoparticles for a specific formulation can be determined by means of routine experimentation, conducted in accordance with the specifications and considerations described herein.
  • concentrations selected as a result of such testing may vary significantly from formulation to formulation, but the concentrations will generally fall within the range of 0.1 to 10 w/v %.
  • the concentration of dispersed smectite clay nanoparticles (e.g., Laponite®) in the compositions of the present invention may vary significantly from formulation to formulation, but is normally within the range of 0.1 to 1 w/v %, and preferably within the range of 0.3 to 0.5 w/v %.
  • the above-described inorganic nanoparticles can be dispersed under physiological pH conditions while retaining a transparent solution, dispersion or gel.
  • the inorganic nanoparticles will form clear and colorless dispersions of low viscosity at concentrations of up to 10 w/v %.
  • the nanoparticles will form clear, highly shear thinning, thixotropic gels. More particularly, at concentrations of greater than 0.5 weight/volume percent (“w/v %”), the particles will form clear gels under appropriate electrolyte conditions and display lubrication, film forming and viscoelastic properties.
  • electrolyte conditions required for the formation of such gels will vary somewhat depending on the particular type of inorganic nanoparticle selected, the concentration utilized, the type of buffer or vehicle involved and other factors apparent to persons skilled in the art.
  • the preferred electrolyte conditions will generally involve the use of very low levels of 1:1 electrolytes (e.g., NaCl).
  • the ideal concentration of the electrolyte in the gel compositions of the present invention can be readily determined through routine experimentation for each formulation.
  • the amount of electrolyte required will generally be on the order of 0.01 to 0.1 w/v %.
  • compositions of the present invention will typically have viscosities that are orders of magnitude higher than the viscosities of compositions that are identical, except for the inclusion of synthetic inorganic nanoparticles.
  • the compositions of the present invention will preferably have a viscosity of less than 5.0 millipascal second (“mPa* sec”) at high shear rates. More specifically, the compositions of the present invention preferably have Newtonian plateau viscosities of less than 5 mPa*sec at shear rates above 25 sec ⁇ 1 , with viscosities in the range of 0.1 to 1 mPa* sec being most preferred.
  • the above-discussed modification of rheological properties provided by the inorganic nanoparticles may be utilized to enhance the retention time of the compositions of the present invention in the eye or ear, or improve the flow characteristics of the compositions.
  • the ophthalmic and otic compositions of the present invention may contain various ancillary substances, in addition to the above-described synthetic inorganic nanoparticles and pharmaceutically active agents, such as buffers and tonicity adjusting agents.
  • the ophthalmic and otic compositions of the present invention will generally be formulated as sterile aqueous solutions, suspensions, dispersions or gels.
  • the compositions must be formulated so as to be compatible with ophthalmic and otic tissues.
  • the ophthalmic solutions, suspensions and dispersions of the present invention will generally have an osmolality of from about 200 to about 400 milliosmoles/kilogram water (“mOsm/kg”). All of the compositions of the invention will have a physiologically compatible pH.
  • the ophthalmic and otic compositions of the present invention that are packaged as multi-dose products may contain one or more ophthalmically acceptable biocides in an amount effective to prevent microbial contamination of the compositions by microbes, such as bacteria and fungi.
  • the biocides utilized for this purpose are referred to herein as “antimicrobial preservatives”.
  • the invention is not limited relative to the types of biocides that may be utilized as antimicrobial preservatives.
  • the preferred biocides include: chlorhexidine, polyhexamethylene biguanide polymers (“PHMB”), polyquaternium-1, and the amino biguanides described in co-pending U.S. patent application Ser. No. 09/581,952 and corresponding International (PCT) Publication No. WO 99/32158, the entire contents of which are hereby incorporated in the present specification by reference.
  • PHMB polyhexamethylene biguanide polymers
  • PCT International
  • the preferred antimicrobial agents are polyquaternium-1 and amino biguanides of the type described in U.S. patent application Ser. No. 09/581,952 and corresponding International (PCT) Publication No. WO 99/32158.
  • the most preferred amino biguanide is identified in U.S. patent application Ser. No. 09/581,952 and corresponding PCT publication as “Compound Number 1”, and has the following structure: This compound is referred to below by means of the code number “AL8496”.
  • compositions may also contain one or more components to enhance the antimicrobial activity of the compositions, such as: a borate/polyol complex (e.g., boric acid/propylene glycol), as described in U.S. Pat. No. 6,143,799 (Chowhan, et al.); a low molecular weight amino alcohol (e.g., AMP), as described in U.S. Pat. No. 6,319,464 B2 (Asgharian); or a low molecular weight amino acid (e.g., glycine), as described in U.S. Pat. No. 5,741,817 (Chowhan, et al.).
  • a borate/polyol complex e.g., boric acid/propylene glycol
  • AMP low molecular weight amino alcohol
  • glycine low molecular weight amino acid
  • the entire contents of the above-referenced patents are hereby incorporated in the present specification by reference.
  • the above-cited components may
  • compositions of the present invention are further illustrated by the representative formulations described in the following examples.

Abstract

The use of nanoparticles of inorganic materials (e.g., synthetic smectite clays) in ophthalmic and otic pharmaceutical compositions is described. The nanoparticles are utilized as biologically inert carriers or depots for ophthalmic and otic drugs. The nanoparticles may also be utilized to modify the rheological properties of the compositions, so as to enhance the viscosity or flow characteristics of the compositions and/or increase the retention time of the compositions in the eye or ear.

Description

    BACKGROUND OF THE INVENTION
  • The present invention is directed to the field of ophthalmic and otic drug delivery. More specifically, the present invention is directed to the use of synthetic, inorganic nanoparticles as inert carriers for ophthalmic and otic drugs, and to the use of pharmaceutical compositions based on the invention to deliver ophthalmic drugs topically to the eye and ear.
  • Many different types of agents have been utilized as carriers for delivering ophthalmic drugs to the eye. For example, the use of carboxyvinyl polymers for this purpose is described in U.S. Pat. No. 4,271,143. Various other organic polymers have also been utilized as carriers for ophthalmic drugs.
  • The use of nanoparticles formed from synthetic or natural polymers in ophthalmic compositions has been described in various scientific publications, such as:
  • Kreuter, J. “Nanoparticles” Colloidal Drug Delivery Systems, edited by Jork Kreuter, Marcel Dekker, New York, N.Y. (USA), chapter 5, page 219 (1994);
  • Gurny, R. “Ocular therapy with nanoparticles” Polymeric Nanoparticles and Microspheres edited by P. Guiot and P. Couvreur, Boca Raton, Fla. (USA): CRC Press, page 127 (1986);
  • Gurny, R. “Preliminary study of prolonged acting drug delivery system for the treatment of glaucoma” Pharm Acta Helv., volume 56, page 130 (1981);
  • Zimmer, et al. “J. Microspheres and nanoparticles used in ocular delivery systems” Advanced Drug Delivery Reviews, volume 16, number 1, pages 61-73 (1995); and
  • Calvo, et al. “Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers” J Pharm Sci, volume 85, number 5. pages 530-536 (May 1996).
  • The nanoparticles utilized in the present invention are not formed from synthetic or natural polymers such as those described in the above-cited publications. Rather, the present invention is directed to the use of inorganic nanoparticles. The nanoparticles utilized in the present invention include, for example, clay substances that are water swellable. An extensive review of clays and their chemical and physical properties can be found in:
  • Giese, R. F. and van Oss C. J., “Colloid and Surface Properties of Clays and Related Minerals”, A. T. Hubbard, Marcel Dekker Inc., Vol. 105.
  • The preferred nanoparticles are formed from synthetic smectite clays which are prepared from simple silicates. The following publications may be referred to for further background regarding the use of synthetic clay nanoparticles in pharmaceutical compositions:
  • Plaizier-Vercammen, “Rheological properties of Laponite XLG, a synthetic purified hectorite” Pharmazie, volume 47, page 856 (1992);
  • Grandolini, et al. “Intercalation compounds of hydrotalcite-like anionic clays with anti-inflammatory agents: I. Intercalation and in vitro release of ibuprofen” International Journal of Pharmaceutics, volume 220, numbers 1-2, pages 23-32 (Jun. 4, 2001);
  • U.S. Pat. No. 5,585,108 (Ruddy, et al.) entitled “Formulations of Oral Gastrointestinal Therapeutic Agents in Combination with Pharmaceutically Acceptable Clays”;
  • U.S. Pat. No. 6,177,480 B1 (Tsuzuki, et al.), which describes the use of a synthetic clay material (i.e., Laponite™) as a wetting agent for contact lenses and to assist in the removal of lipid deposits from contact lenses by surfactants;
  • U.S. Pat. No. 6,015,816 (Kostyniak, et al.), which describes an improved method using colloid particles, such as smectite clay minerals, as a substrate for ligands having antimicrobial activity, so as to control microbial growth on a material; and
  • U.S. Pat. No. 6,177,480 (Tsuzuki, et al.) describes the use of synthetic clay material (i.e., Laponite™) as a wetting agent for contact lenses and to assist in the removal of lipid deposits from contact lenses by surfactants.
  • SUMMARY OF THE INVENTION
  • The present invention is based on the use of nanoparticles of inorganic materials to facilitate the formulation of ophthalmic and otic compositions, particularly compositions adapted for topical application to ophthalmic or otic tissues. The nanoparticles function as a chemically inert carrier or depot for ophthalmic and otic drugs and other components of ophthalmic and otic compositions.
  • The present invention is believed to have advantages over the prior art use of organic polymers for ophthalmic drug delivery. For example, the inorganic nanoparticles utilized in the present invention are particularly well suited for use as drug delivery agents in instances wherein controlled delivery of the drug is needed. The particles offer advantages over current state of the art delivery agents as a result of the higher surface area of the particles and the ability of the particles to form clear gels or solutions when dispersed in aqueous media.
  • It has been found that at very low concentrations in aqueous solutions, the nanoparticles can be dispersed while retaining a clear solution. Due to the minute size of the nanoparticles, the compositions of the present invention remain clear and non-blurry, which is very important for ophthalmic compositions. It has also been found that the particles can be utilized as carriers for ophthalmic and otic drugs without compromising the microbiological activity of antimicrobial preservatives contained in the compositions.
  • In addition to acting as inert carriers for ophthalmic and otic drugs, the inorganic nanoparticles also provide advantageous rheological properties for the compositions of the present invention.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The nanoparticles utilized in the present invention are inorganic materials. The particles have colloidal dimensions, a large surface area and a high ion exchange capacity. The particles are generally referred to hereinafter as “inorganic nanoparticles”. The use of the synthetic inorganic nanoparticles is preferred.
  • The inorganic nanoparticles used in the present invention preferably have particle dimensions less than 100 nanometers (“nm”), but greater than 1 nm. The morphology of the nanoparticles is not limited to being spherical; plate-like, cubic, ellipsoid or other particle shapes are also useful. The particles have surface areas ranging from 30-1000 square meters/gram (“m2/g”), and have an overall negative surface charge at a pH in the range of 6.0 to 7.8.
  • The inorganic nanoparticles utilized in the present invention may also be surface modified, depending on the particular type of composition involved and stability requirements. Different types of nanoparticles may be combined to optimize the formulation properties.
  • The inorganic nanoparticles utilized in the present invention are preferably formed from clays that swell in aqueous solutions. These types of clays are referred to herein as being “hydrous”. The use of nanoparticles of synthetic hydrous clays is preferred due to the commercial availability, purity, and well-defined chemical composition and physical properties of these materials. In addition, the synthetic clay nanoparticles are easier to formulate and can form colorless and transparent gels more readily than inorganic nanoparticles formed from naturally occurring clays.
  • Synthetic inorganic nanoparticles that are particularly useful include a synthetic smectite clay that is commercially available under the trademark Laponite® (Southern Clay Products, Gonzales, Tex., USA). Laponite® is a layered hydrous magnesium silicate prepared from simple silicates. The following publication may be referred to for further details concerning the physical properties and functions of Laponite®: “Laponite Technical Bulletin “Laponite-synthetic layered silicate—its chemistry, structure and relationship to natural clays” L204/01 g. Another synthetic magnesium aluminum silicate material is also commercially available under the trademark OPTIGEL® SH (Sud-Chemie, Louisville, Ky.).
  • Inorganic nanoparticles formed from naturally occurring hydrous clays may also be utilized, either in combination with a synthetic clay or alone. Examples of suitable naturally occurring clays include aliettite, beidellite, bentonite, hectorite, kaolinite, magadite, montmorillonite, nontronite, saponite, sauconite, stevensite and volkonskoite.
  • The following publications may be referred to for further details regarding the physical properties of various types of clay nanoparticles and the use of these materials as ion-exchange materials, viscosity modifiers and film forming agents:
  • Gieseking, J. E., “Mechanism of Cation Exchange in the Mont-Morillonite-Beidellite-Nontronite Type of Clay Minerals”, Soil Science, volume 47, pages 1-14 (1939);
  • Theng, B. K. G., “Formation and Properties of Clay-Polymer Complexes”, Elsevier, Amsterdam, (1979); and
  • H. van Olphen, “Clay Colloid Chemistry”, Krieger Publishing Company, Florida, Second Edition (1991).
  • Examples of other inorganic nanoparticle materials that may be utilized instead of or in combination with the clay nanoparticles described above include zeolites, silica, aluminum oxide, cerium oxide, titanium oxide and zinc oxide. Nanometer sized silica particles, such as those supplied by Nalco (e.g., Nalco® 115 and 1140) and EKA Chemicals (NYACOL® grades), are readily available. Mineral oxide nanoparticles based on other metals are also commercially available. For example, mineral oxides (e.g., aluminum oxide, cerium oxide, titanium oxide and zinc oxide) having well defined nano-dimensions are available from Nanophase Technologies (Romeoville, Ill., USA) under the trade name “NanoTek®”.
  • As indicated above, it has been discovered that the above-described inorganic nanoparticles are capable of functioning as carriers for ophthalmic and otic drug molecules and other components of ophthalmic and otic pharmaceutical compositions. The present invention is applicable to the use of nanoparticles as carriers for various types of pharmaceutically active agents, such as agents for controlling intraocular pressure and treating glaucoma, neuroprotectants, anti-allergy agents, anti-infectives, anti-inflammatory agents, mucosecretagogues, angiostatic steroids, pain relievers, decongestants or astringents, and so on.
  • Examples of pharmaceutically active agents which may be included in the compositions of the present invention, and administered via the methods of the present invention include, but are not limited to: anti-glaucoma agents, such as apraclonidine, brimonidine, betaxolol, timolol, pilocarpine, carbonic anhydrase inhibitors, prostaglandins and serotonergics; dopaminergic antagonists; anti-infectives, such as moxifloxacin, gatifloxacin, levofloxacin, ciprofloxacin and tobramycin; non-steroidal and steroidal anti-inflammatories, such as rimexolone, dexamethasone, prednisolone, fluorometholone, lotoprednol, naproxen, diclofenac, suprofen and ketorolac; proteins; growth factors, such as epidermal growth factor; mucosecretagogues, such as 15-HETE; angiostatic steroids, such as anecortave acetate; antihistamines, such as emadine; mast cell stabilizers, such as olopatadine; and immunomodulators, such as cyclosporin.
  • The concentration of the inorganic nanoparticles utilized in specific ophthalmic or otic compositions of the present invention will depend on the physical form of the composition (e.g., solution, dispersion, suspension or gel) and other factors apparent to those skilled in the art. The identification of an ideal concentration of nanoparticles for a specific formulation can be determined by means of routine experimentation, conducted in accordance with the specifications and considerations described herein. The ideal concentrations selected as a result of such testing may vary significantly from formulation to formulation, but the concentrations will generally fall within the range of 0.1 to 10 w/v %. The concentration of dispersed smectite clay nanoparticles (e.g., Laponite®) in the compositions of the present invention may vary significantly from formulation to formulation, but is normally within the range of 0.1 to 1 w/v %, and preferably within the range of 0.3 to 0.5 w/v %.
  • It has been found that at low concentrations in aqueous buffered solutions, the above-described inorganic nanoparticles can be dispersed under physiological pH conditions while retaining a transparent solution, dispersion or gel. The inorganic nanoparticles will form clear and colorless dispersions of low viscosity at concentrations of up to 10 w/v %. However, if combined with appropriate amounts of salts and other excipients, the nanoparticles will form clear, highly shear thinning, thixotropic gels. More particularly, at concentrations of greater than 0.5 weight/volume percent (“w/v %”), the particles will form clear gels under appropriate electrolyte conditions and display lubrication, film forming and viscoelastic properties.
  • The electrolyte conditions required for the formation of such gels will vary somewhat depending on the particular type of inorganic nanoparticle selected, the concentration utilized, the type of buffer or vehicle involved and other factors apparent to persons skilled in the art. However, the preferred electrolyte conditions will generally involve the use of very low levels of 1:1 electrolytes (e.g., NaCl). The ideal concentration of the electrolyte in the gel compositions of the present invention can be readily determined through routine experimentation for each formulation. However, the amount of electrolyte required will generally be on the order of 0.01 to 0.1 w/v %.
  • The incorporation of inorganic nanoparticles in aqueous ophthalmic and otic compositions as described herein results in significant rheological changes. The compositions of the present invention will typically have viscosities that are orders of magnitude higher than the viscosities of compositions that are identical, except for the inclusion of synthetic inorganic nanoparticles. The compositions of the present invention will preferably have a viscosity of less than 5.0 millipascal second (“mPa* sec”) at high shear rates. More specifically, the compositions of the present invention preferably have Newtonian plateau viscosities of less than 5 mPa*sec at shear rates above 25 sec−1, with viscosities in the range of 0.1 to 1 mPa* sec being most preferred.
  • The above-discussed modification of rheological properties provided by the inorganic nanoparticles may be utilized to enhance the retention time of the compositions of the present invention in the eye or ear, or improve the flow characteristics of the compositions.
  • The ophthalmic and otic compositions of the present invention may contain various ancillary substances, in addition to the above-described synthetic inorganic nanoparticles and pharmaceutically active agents, such as buffers and tonicity adjusting agents. The ophthalmic and otic compositions of the present invention will generally be formulated as sterile aqueous solutions, suspensions, dispersions or gels. The compositions must be formulated so as to be compatible with ophthalmic and otic tissues. The ophthalmic solutions, suspensions and dispersions of the present invention will generally have an osmolality of from about 200 to about 400 milliosmoles/kilogram water (“mOsm/kg”). All of the compositions of the invention will have a physiologically compatible pH.
  • The ophthalmic and otic compositions of the present invention that are packaged as multi-dose products may contain one or more ophthalmically acceptable biocides in an amount effective to prevent microbial contamination of the compositions by microbes, such as bacteria and fungi. The biocides utilized for this purpose are referred to herein as “antimicrobial preservatives”.
  • The invention is not limited relative to the types of biocides that may be utilized as antimicrobial preservatives. The preferred biocides include: chlorhexidine, polyhexamethylene biguanide polymers (“PHMB”), polyquaternium-1, and the amino biguanides described in co-pending U.S. patent application Ser. No. 09/581,952 and corresponding International (PCT) Publication No. WO 99/32158, the entire contents of which are hereby incorporated in the present specification by reference. The use of surface-active biocides is preferred.
  • The preferred antimicrobial agents are polyquaternium-1 and amino biguanides of the type described in U.S. patent application Ser. No. 09/581,952 and corresponding International (PCT) Publication No. WO 99/32158. The most preferred amino biguanide is identified in U.S. patent application Ser. No. 09/581,952 and corresponding PCT publication as “Compound Number 1”, and has the following structure:
    Figure US20050003014A1-20050106-C00001

    This compound is referred to below by means of the code number “AL8496”.
  • The levels of antimicrobial activity required to preserve ophthalmic and otic pharmaceutical compositions from microbial contamination are well known to those skilled in the art, based both on personal experience and official, published standards, such as those set forth in the United States Pharmacopoeia (“USP”) and similar publications in other countries. The amount of antimicrobial preservative required for this purpose is referred to herein as “an effective amount”.
  • The compositions may also contain one or more components to enhance the antimicrobial activity of the compositions, such as: a borate/polyol complex (e.g., boric acid/propylene glycol), as described in U.S. Pat. No. 6,143,799 (Chowhan, et al.); a low molecular weight amino alcohol (e.g., AMP), as described in U.S. Pat. No. 6,319,464 B2 (Asgharian); or a low molecular weight amino acid (e.g., glycine), as described in U.S. Pat. No. 5,741,817 (Chowhan, et al.). The entire contents of the above-referenced patents are hereby incorporated in the present specification by reference. The above-cited components may be used either alone or in combination with conventional antimicrobial agents such as polyquaternium-1.
  • The compositions of the present invention are further illustrated by the representative formulations described in the following examples.
  • EXAMPLES
  • The table below provides examples of opthalmic drug suspensions containing rimexolone. These compositions are useful in the treatment of ocular inflammation. All concentrations in the table are expressed as weight/volume percent.
    9534- 9534- 9534- 9534- 9534- 9534- 9534- 9534- 9534-
    Ingredient 38A 38B 38C 38D 38E 38F 38G 38H 38I
    Laponite ® XLG 0.25 0.125 0.05 0.5 0.25 0.5 0.5 0.25 0.25
    Rimexolone 0.1 0.1 0.1 0.1 0.1 0.1
    BAC 0.01 0.01
    AL-8496A 0.0004 0.0004
    Poloxamine 1304 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
    Tween 80 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
    EDTA 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
    Sodium Chloride 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4
    Propylene Glycol 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
    HPMC 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4
    Sodium Borate 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4
    Purified Water QS QS QS QS QS QS QS QS QS
    pH 7.8 7.8 7.8 7.8 7.8 7.8 7.8 7.8 7.8
    *Viscosity mPas · s 7.89 ± 9.78 ± 10.09 ± 13.20 ± 12.36 ± TBD TBD TBD TBD
    at 61.15 s−1 0.251 0.32 0.30 0.01 0.54

    *Determined using Brookfied DVIII+ − ULA spindle-room temperature-not controlled

Claims (8)

1. Use of synthetic inorganic nanoparticles as carriers for ophthalmic or otic drugs.
2. A method of delivering a drug to the eye or ear, which comprises utilizing synthetic inorganic nanoparticles as carriers for the drug.
3. An ophthalmic or otic pharmaceutical composition comprising a therapeutically effective amount of an ophthalmic or otic drug and an amount of synthetic inorganic nanoparticles sufficient to carry the drug.
4. A composition according to claim 3 wherein the nanoparticles have: (a) particle dimensions less than 100 nm, but greater than 1 nm, with a standard deviation of the distribution of less than 10%; (b) surface areas ranging from 30 to 1000 m2/g; and (c) an overall negative surface charge at a pH in the range of 6.0 to 7.8.
5. A composition according to claims 3 or 4, wherein the nanoparticles are formed form a synthetic hydrous clay
6. A composition according to claim 5, wherein the synthetic hydrous clay is a smectite clay.
7. A composition according to claims 3 or 4, wherein the nanoparticles are selected from the group consisting of zealites, hydrotalcite, silica, aluminum oxide, cerium oxide, titanium oxide and zinc oxide.
8. A composition according to any one of claims 3 to 7, wherein the concentration of the nanoparticles in the composition is 0.000001 to 10 w/v %.
US10/494,709 2001-12-21 2002-12-20 Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs Abandoned US20050003014A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/494,709 US20050003014A1 (en) 2001-12-21 2002-12-20 Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs
US13/186,108 US8257745B2 (en) 2001-12-21 2011-07-19 Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34298301P 2001-12-21 2001-12-21
US10/494,709 US20050003014A1 (en) 2001-12-21 2002-12-20 Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs
PCT/US2002/041248 WO2003059194A2 (en) 2001-12-21 2002-12-20 Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/186,108 Continuation US8257745B2 (en) 2001-12-21 2011-07-19 Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs

Publications (1)

Publication Number Publication Date
US20050003014A1 true US20050003014A1 (en) 2005-01-06

Family

ID=23344163

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/494,709 Abandoned US20050003014A1 (en) 2001-12-21 2002-12-20 Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs
US13/186,108 Expired - Fee Related US8257745B2 (en) 2001-12-21 2011-07-19 Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/186,108 Expired - Fee Related US8257745B2 (en) 2001-12-21 2011-07-19 Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs

Country Status (19)

Country Link
US (2) US20050003014A1 (en)
EP (1) EP1474109B1 (en)
JP (1) JP2005514429A (en)
KR (1) KR100990810B1 (en)
CN (1) CN100441169C (en)
AT (1) ATE478657T1 (en)
AU (1) AU2002367029B2 (en)
BR (1) BR0215238A (en)
CA (1) CA2467763C (en)
DE (1) DE60237475D1 (en)
DK (1) DK1474109T3 (en)
ES (1) ES2349235T3 (en)
HK (1) HK1075001A1 (en)
MX (1) MXPA04004919A (en)
PL (1) PL211494B1 (en)
PT (1) PT1474109E (en)
SI (1) SI1474109T1 (en)
WO (1) WO2003059194A2 (en)
ZA (1) ZA200403666B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100098768A1 (en) * 2008-10-16 2010-04-22 Clarkson University Method of neuroprotection from oxidant injury using metal oxide nanoparticles
WO2012074588A2 (en) 2010-08-30 2012-06-07 President And Fellows Of Harvard College Shear controlled release for stenotic lesions and thrombolytic therapies
US9238006B2 (en) * 2012-08-07 2016-01-19 Korea Research Institute Of Standards And Science Composition containing inorganic nanoparticles as an active ingredient for preventing or treating of angiogenesis-related diseases
WO2022072348A1 (en) 2020-09-29 2022-04-07 Oxford University Innovation Limited Stroke treatment

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1455804A4 (en) * 2001-12-21 2005-01-05 Alcon Inc Use of nanoparticles as carriers for biocides in ophthalmic compositions
EP1474109B1 (en) 2001-12-21 2010-08-25 Alcon, Inc. Use of synthetic inorganic nanoparticles as carriers for ophthalmic drugs
JP2005514433A (en) * 2001-12-21 2005-05-19 アルコン、インコーポレイテッド Use of inorganic nanoparticles to modify viscosity and other physical properties of ophthalmic / ear pharmaceutical compositions
CA2549994A1 (en) 2002-12-18 2004-08-12 Hough Ear Institute Otologic nanotechnology
US8651113B2 (en) 2003-06-18 2014-02-18 Swr&D Inc. Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
US7723311B2 (en) 2003-06-18 2010-05-25 Nanobiomagnetics, Inc. Delivery of bioactive substances to target cells
US7344491B1 (en) 2003-11-26 2008-03-18 Nanobiomagnetics, Inc. Method and apparatus for improving hearing
EP2112196A1 (en) * 2008-04-25 2009-10-28 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO A liquid composition comprising polymer chains and particles of an inorganic material in a liquid
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN104531671A (en) 2010-10-01 2015-04-22 现代治疗公司 Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2015501844A (en) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. Modified nucleosides, nucleotides and nucleic acid compositions
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
CN104411338A (en) 2012-04-02 2015-03-11 现代治疗公司 Modified polynucleotides for the production of biologics and proteins associated with human disease
DE18200782T1 (en) 2012-04-02 2021-10-21 Modernatx, Inc. MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH DISEASES IN HUMANS
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
HRP20220607T1 (en) 2012-11-26 2022-06-24 Modernatx, Inc. Terminally modified rna
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
EA201690675A1 (en) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. POLYNUCLEOTES ENCODING THE RECEPTOR OF LOW DENSITY LIPOPROTEINS
CL2013003807A1 (en) * 2013-12-31 2014-07-11 Univ Santiago Chile Small silicone tube devices containing nanoparticles and zeolite microparticles as prolonged and controlled release agents, loaded with 2-methoxystradiol and suspended in an oily medium that also contains 2-methoxystradiol.
EP3169693B1 (en) 2014-07-16 2022-03-09 ModernaTX, Inc. Chimeric polynucleotides
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
WO2016016908A1 (en) * 2014-07-28 2016-02-04 Sun Pharma Advanced Research Company Limited Method of increasing bioavailability and/or prolonging ophthalmic action of a drug
WO2017007796A1 (en) 2015-07-06 2017-01-12 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
KR101748120B1 (en) * 2015-07-13 2017-06-16 서울대학교산학협력단 Compositions comprising nanoparticle-protein complex based on vitreous as an active ingredient for inhibiting angiogenesis, and uses thereof
RS63135B1 (en) 2015-12-23 2022-05-31 Modernatx Inc Methods of using ox40 ligand encoding polynucleotides
WO2017120612A1 (en) 2016-01-10 2017-07-13 Modernatx, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
US11077051B2 (en) 2016-09-15 2021-08-03 University of Pittsburgh—of the Commonwealth System of Higher Education Shear-thinning therapeutic composition, and related methods
JP7285220B2 (en) 2017-05-18 2023-06-01 モデルナティエックス インコーポレイテッド Lipid nanoparticles comprising linked interleukin-12 (IL12) polypeptide-encoding polynucleotides
EP3635009A1 (en) 2017-06-07 2020-04-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
US20200399623A1 (en) 2018-02-07 2020-12-24 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
CN109045305B (en) * 2018-07-31 2021-12-10 东华大学 Preparation method of TPGS-modified hectorite nanoparticles
CA3125511A1 (en) 2019-02-08 2020-08-13 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
EP3851097A1 (en) * 2020-01-15 2021-07-21 Universidad De Zaragoza Controlled release formulations
US20230272052A1 (en) 2020-07-31 2023-08-31 CureVac SE Nucleic acid encoded antibody mixtures
CA3195696A1 (en) 2020-09-17 2022-03-24 Restore Vision Inc. Composition for treating or preventing diseases, disorders, or conditions associated with endoplasmic reticulum stress or all-trans-retinal, protecting retinal thickness, or suppressing reduction in retinal thickness or progress of reduction in retinal thickness
WO2023133579A1 (en) 2022-01-10 2023-07-13 Regeneron Pharmaceuticals, Inc. Bbb-targeted gaa delivered as gene therapy treats cns and muscle in pompe disease model mice
WO2023220603A1 (en) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle

Citations (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3884826A (en) * 1973-07-20 1975-05-20 Barnes Hind Pharm Inc Thixotropic cleaning agent for hard contact lenses
US4127423A (en) * 1977-09-13 1978-11-28 Burton, Parsons And Company, Inc. Contact lens cleaning solution
US4271143A (en) * 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4365030A (en) * 1974-09-27 1982-12-21 Exxon Research And Engineering Co. Overtreated higher dialkyl dimethyl ammonium clay gellants
US4374745A (en) * 1981-08-13 1983-02-22 Barnes-Hind Pharmaceuticals, Inc. Cleaning compositions
US4394179A (en) * 1979-06-25 1983-07-19 Polymer Technology Corporation Abrasive-containing contact lens cleaning materials
US4738851A (en) * 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US4804539A (en) * 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4847078A (en) * 1987-01-14 1989-07-11 Arseco, Inc. Storage stable topical composition having moisture control agent
US4891043A (en) * 1987-05-28 1990-01-02 Board Of Trustees Of The University Of Illinois System for selective release of liposome encapsulated material via laser radiation
US4923699A (en) * 1988-06-03 1990-05-08 Kaufman Herbert E Eye treatment suspension
US4940701A (en) * 1984-01-25 1990-07-10 Beecham Group P.L.C. Topical drug release system
US5037647A (en) * 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5139782A (en) * 1991-12-23 1992-08-18 Uop Facial cleansing mineral compositions
US5185152A (en) * 1990-01-10 1993-02-09 Peyman Gholam A Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye
US5212162A (en) * 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5403598A (en) * 1991-12-13 1995-04-04 Alcon Laboratories, Inc. Physiological tear compositions and methods for their preparation
US5585108A (en) * 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5654262A (en) * 1993-12-22 1997-08-05 Alcon Laboratories, Inc. Contact lens cleaning composition containing polyalkylene oxide modified siloxanes
US5674504A (en) * 1989-07-12 1997-10-07 L'oreal Cosmetic composition in the form of an aqueous gel containing in suspension spheroids of a non-hydrophilic, lipoidal substance
US5741817A (en) * 1994-07-22 1998-04-21 Chowhan; Masood Use of low molecular weight amino acids in ophthalmic compositions
US5811580A (en) * 1996-12-04 1998-09-22 The Lubrizol Corporation Process for the preparation of N-hydrocarbyl-substituted amides via the ritter reaction using solid clay catalysts
US5858346A (en) * 1997-05-09 1999-01-12 Allergan Compositions and methods for enhancing contact lens wearability
US6015816A (en) * 1996-02-29 2000-01-18 The Research Foundation Of State University Of New York Antimicrobial compositions
US6024941A (en) * 1992-07-13 2000-02-15 Shiseido Company, Ltd. External skin treatment composition
US6143799A (en) * 1992-05-06 2000-11-07 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US6177480B1 (en) * 1998-03-27 2001-01-23 Menicon Co., Ltd. Agent for contact lenses
US6180093B1 (en) * 1996-09-20 2001-01-30 Bausch & Lomb Incorporated Method and composition for rewetting contact lenses and relieving eye dryness
US6271224B1 (en) * 1995-12-21 2001-08-07 Alcon Laboratories, Inc. Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
US6319464B1 (en) * 1996-12-13 2001-11-20 Alcon Manufacturing, Ltd. Use of low molecular weight amino alcohols in ophthalmic compositions
US6319513B1 (en) * 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
US20020035264A1 (en) * 2000-07-13 2002-03-21 Kararli Tugrul T. Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug
US6403609B1 (en) * 1997-07-29 2002-06-11 Alcon Manufacturing, Ltd. Ophthalmic compositions containing galactomannan polymers and borate
US20030225356A1 (en) * 2002-05-24 2003-12-04 Kulichikhin Valery G. Composition for cushions, wound dressings and other skin-contacting products
US20040076682A1 (en) * 2001-02-15 2004-04-22 Toshiyuki Kohzaki Novel ophthalmic compositions
US20040096477A1 (en) * 2002-06-05 2004-05-20 Anuj Chauhan Ophthalmic drug delivery system
US20050181015A1 (en) * 2004-02-12 2005-08-18 Sheng-Ping (Samuel) Zhong Layered silicate nanoparticles for controlled delivery of therapeutic agents from medical articles
US20060193787A1 (en) * 2005-01-31 2006-08-31 Si-Shen Feng Nanoparticle-based drug delivery system

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US627124A (en) * 1899-06-20 Fan attachment for sewing-machines
US3947573A (en) 1969-12-01 1976-03-30 Burton, Parsons And Company, Inc. Opthalmic solution
US4120949A (en) 1977-10-05 1978-10-17 Cooper Laboratories, Inc. Ophthalmic solution
GB8401965D0 (en) * 1984-01-25 1984-02-29 Beecham Group Plc Composition
EP0217440A1 (en) * 1985-09-27 1987-04-08 The Procter & Gamble Company Stable aqueous pharmaceutical suspensions
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
WO1988004168A1 (en) * 1986-12-08 1988-06-16 Arseco, Inc. A storage stable topical composition
WO1988005073A1 (en) 1986-12-24 1988-07-14 Alcon Laboratories, Inc. Contact lens cleaning composition and method of use
JP2536806B2 (en) * 1991-03-27 1996-09-25 アルコン ラボラトリーズ インコーポレイテッド Topical ophthalmic composition combining gelled polysaccharide and finely divided drug carrier
JP3736916B2 (en) 1996-02-19 2006-01-18 株式会社サンコンタクトレンズ Disinfecting composition for hydrous soft contact lens and its use
DE69806498T2 (en) 1997-11-12 2003-01-16 Bausch & Lomb TREATMENT OF CONTACT LENSES WITH AQUEOUS ALKALICARBONATE SOLUTIONS
ZA9811445B (en) 1997-12-19 1999-08-16 Alcon Lab Inc Aminobiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions.
US20010016577A1 (en) * 1998-08-24 2001-08-23 Douglas Joseph Dobrozsi Oral mucoadhesive compositions containing gastrointestinal actives
FR2783419B1 (en) 1998-09-18 2002-07-12 Oreal USE OF MIXED SILICATES AT PH ACID AS TENSIONING AGENTS IN ANTI-WRINKLE COSMETIC COMPOSITIONS
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6333054B1 (en) * 1999-10-21 2001-12-25 Amuchina S.P.A. Topical, non-cytotoxic, antimicrobial hydrogel with thixotropic properties
JP2001240547A (en) * 2000-02-29 2001-09-04 Lion Corp Inhibitor of pollinosis
US20030043341A1 (en) 2001-08-02 2003-03-06 Turner David C. Antimicrobial lenses and methods of their use
EP1474109B1 (en) 2001-12-21 2010-08-25 Alcon, Inc. Use of synthetic inorganic nanoparticles as carriers for ophthalmic drugs
JP2005514433A (en) * 2001-12-21 2005-05-19 アルコン、インコーポレイテッド Use of inorganic nanoparticles to modify viscosity and other physical properties of ophthalmic / ear pharmaceutical compositions

Patent Citations (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3884826A (en) * 1973-07-20 1975-05-20 Barnes Hind Pharm Inc Thixotropic cleaning agent for hard contact lenses
US4365030A (en) * 1974-09-27 1982-12-21 Exxon Research And Engineering Co. Overtreated higher dialkyl dimethyl ammonium clay gellants
US4127423A (en) * 1977-09-13 1978-11-28 Burton, Parsons And Company, Inc. Contact lens cleaning solution
US4271143A (en) * 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4394179A (en) * 1979-06-25 1983-07-19 Polymer Technology Corporation Abrasive-containing contact lens cleaning materials
US4374745A (en) * 1981-08-13 1983-02-22 Barnes-Hind Pharmaceuticals, Inc. Cleaning compositions
US4940701A (en) * 1984-01-25 1990-07-10 Beecham Group P.L.C. Topical drug release system
US4738851A (en) * 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US4804539A (en) * 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4847078A (en) * 1987-01-14 1989-07-11 Arseco, Inc. Storage stable topical composition having moisture control agent
US4891043A (en) * 1987-05-28 1990-01-02 Board Of Trustees Of The University Of Illinois System for selective release of liposome encapsulated material via laser radiation
US4923699A (en) * 1988-06-03 1990-05-08 Kaufman Herbert E Eye treatment suspension
US5037647A (en) * 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5674504A (en) * 1989-07-12 1997-10-07 L'oreal Cosmetic composition in the form of an aqueous gel containing in suspension spheroids of a non-hydrophilic, lipoidal substance
US5185152A (en) * 1990-01-10 1993-02-09 Peyman Gholam A Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye
US5212162A (en) * 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5403598A (en) * 1991-12-13 1995-04-04 Alcon Laboratories, Inc. Physiological tear compositions and methods for their preparation
US5139782A (en) * 1991-12-23 1992-08-18 Uop Facial cleansing mineral compositions
US6143799A (en) * 1992-05-06 2000-11-07 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US6024941A (en) * 1992-07-13 2000-02-15 Shiseido Company, Ltd. External skin treatment composition
US5654262A (en) * 1993-12-22 1997-08-05 Alcon Laboratories, Inc. Contact lens cleaning composition containing polyalkylene oxide modified siloxanes
US5741817A (en) * 1994-07-22 1998-04-21 Chowhan; Masood Use of low molecular weight amino acids in ophthalmic compositions
US5585108A (en) * 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US6271224B1 (en) * 1995-12-21 2001-08-07 Alcon Laboratories, Inc. Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
US6015816A (en) * 1996-02-29 2000-01-18 The Research Foundation Of State University Of New York Antimicrobial compositions
US6180093B1 (en) * 1996-09-20 2001-01-30 Bausch & Lomb Incorporated Method and composition for rewetting contact lenses and relieving eye dryness
US5811580A (en) * 1996-12-04 1998-09-22 The Lubrizol Corporation Process for the preparation of N-hydrocarbyl-substituted amides via the ritter reaction using solid clay catalysts
US6319464B1 (en) * 1996-12-13 2001-11-20 Alcon Manufacturing, Ltd. Use of low molecular weight amino alcohols in ophthalmic compositions
US5858346A (en) * 1997-05-09 1999-01-12 Allergan Compositions and methods for enhancing contact lens wearability
US6403609B1 (en) * 1997-07-29 2002-06-11 Alcon Manufacturing, Ltd. Ophthalmic compositions containing galactomannan polymers and borate
US6177480B1 (en) * 1998-03-27 2001-01-23 Menicon Co., Ltd. Agent for contact lenses
US6319513B1 (en) * 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
US20020035264A1 (en) * 2000-07-13 2002-03-21 Kararli Tugrul T. Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug
US20040076682A1 (en) * 2001-02-15 2004-04-22 Toshiyuki Kohzaki Novel ophthalmic compositions
US20030225356A1 (en) * 2002-05-24 2003-12-04 Kulichikhin Valery G. Composition for cushions, wound dressings and other skin-contacting products
US20040096477A1 (en) * 2002-06-05 2004-05-20 Anuj Chauhan Ophthalmic drug delivery system
US20050181015A1 (en) * 2004-02-12 2005-08-18 Sheng-Ping (Samuel) Zhong Layered silicate nanoparticles for controlled delivery of therapeutic agents from medical articles
US20060193787A1 (en) * 2005-01-31 2006-08-31 Si-Shen Feng Nanoparticle-based drug delivery system

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100098768A1 (en) * 2008-10-16 2010-04-22 Clarkson University Method of neuroprotection from oxidant injury using metal oxide nanoparticles
WO2012074588A2 (en) 2010-08-30 2012-06-07 President And Fellows Of Harvard College Shear controlled release for stenotic lesions and thrombolytic therapies
US9238006B2 (en) * 2012-08-07 2016-01-19 Korea Research Institute Of Standards And Science Composition containing inorganic nanoparticles as an active ingredient for preventing or treating of angiogenesis-related diseases
WO2022072348A1 (en) 2020-09-29 2022-04-07 Oxford University Innovation Limited Stroke treatment

Also Published As

Publication number Publication date
ES2349235T3 (en) 2010-12-29
CA2467763A1 (en) 2003-07-24
BR0215238A (en) 2005-05-31
HK1075001A1 (en) 2005-12-02
CN100441169C (en) 2008-12-10
AU2002367029A1 (en) 2003-07-30
JP2005514429A (en) 2005-05-19
KR100990810B1 (en) 2010-10-29
US20110274760A1 (en) 2011-11-10
EP1474109A4 (en) 2006-03-29
DE60237475D1 (en) 2010-10-07
ZA200403666B (en) 2005-07-27
EP1474109B1 (en) 2010-08-25
CA2467763C (en) 2011-09-13
PT1474109E (en) 2010-10-25
EP1474109A2 (en) 2004-11-10
PL211494B1 (en) 2012-05-31
WO2003059194A3 (en) 2004-05-13
CN1604770A (en) 2005-04-06
ATE478657T1 (en) 2010-09-15
KR20040072669A (en) 2004-08-18
MXPA04004919A (en) 2004-08-11
SI1474109T1 (en) 2010-11-30
US8257745B2 (en) 2012-09-04
AU2002367029B2 (en) 2008-10-02
WO2003059194A2 (en) 2003-07-24
DK1474109T3 (en) 2010-10-25
PL374262A1 (en) 2005-10-03

Similar Documents

Publication Publication Date Title
US8257745B2 (en) Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs
US20050002970A1 (en) Inorganic nanopartices to modify the viscosity and physical properties of ophthalmic and otic compositions
US8097270B2 (en) Use of nanoparticles as carriers for biocides in ophthalmic compositions
JP2012528889A (en) Fluticasone ophthalmic formulation and method of use
CN1129400A (en) Use of vitamin E. Tocopheryl derivatives in ophthalmic compositions
JP2536806B2 (en) Topical ophthalmic composition combining gelled polysaccharide and finely divided drug carrier
CA2104917C (en) Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
EP0590786B1 (en) Use of certain anionic surfactants to enhance antimicrobial effectiveness of opthalmic compositions
HU223070B1 (en) Ophthalmic composition containing an ion sensitive, hydrophilic polymer and an inorganic salt in a ratio which gives low viscosity
WO2008002118A1 (en) An ophthalmic formulation in suspension of loteprednol etabonate and ciprofloxacin hydrochloride
EP2827838B1 (en) Ophthalmic pharmaceutical composition containing a carbonic anhydrase inhibitor and method for the preparation thereof
WO2018215638A1 (en) Pharmaceutical compositions comprising azithromycin
AU2002367028B2 (en) Use of nanoparticles as carriers for biocides in ophthalmic compositions
US20220071994A1 (en) Ophthalmic formulations for the treatment of presbyopia

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALCON, INC., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KETELSON, HOWARD ALLEN;MEADOWS, DAVID L.;REEL/FRAME:015712/0639;SIGNING DATES FROM 20040414 TO 20040415

AS Assignment

Owner name: ALCON, INC., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KETELSON, HOWARD ALLEN;MEADOWS, DAVID L.;REEL/FRAME:015694/0739;SIGNING DATES FROM 20040414 TO 20040415

AS Assignment

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: MERGER;ASSIGNOR:ALCON, INC.;REEL/FRAME:026376/0076

Effective date: 20110408

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION